IDENIX PROVIDES UPDATE ON DEVELOPMENT PROGRAM FOR VALOPICITABINE
Idenix Pharmaceuticals will begin a Phase III clinical trial of Valopicitabine
in treatment-refractory hepatitis C (HCV) patients by the end of the first quarter
of 2006. The company is currently sponsoring a Phase IIb clinical trial in treatment-refractory
patients, which includes a patient cohort receiving valopicitabine 800 mg plus
pegylated interferon.
Valopicitabine, which is administered orally, is intended to block HCV replication
by specifically inhibiting the HCV RNA polymerase, the enzyme that makes new
copies of HCV viral chromosome inside infected cells. The ongoing clinical trials
are designed to evaluate the combination of valopicitabine and pegylated interferon
in HCV Genotype 1 patients who previously failed to respond to antiviral treatment,
as well as in Genotype 1 patients who have not been treated previously. Preliminary
results from trials to date have demonstrated that the antiviral effect of valopicitabine
is enhanced when this agent is used in combination with pegylated interferon.